Indirect Treatment Comparisons and Network Meta-analyses for Managers and Directors

(7:18)

Matching-adjusted indirect comparison of liso-cel vs axi-cel in the 2L treatment of R/R LBCL

(59)

Introduction to Indirect Treatment Comparison Part 1

(5:29)

Matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA

(4:1econd)

Indirect comparison of elranatamab in MagnetisMM-3 versus real-world treatment regimens

(1:35)

Indirect comparison of momelotinib vs pacritinib safety and anemia outcomes in myelofibrosis

(1:28)

Dr. Lucia Masarova Discusses Indirect Comparison of Pacritinib and Momelotinib in Myelofibrosis

(7:40)

Indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis

(1:16)

Matching-adjusted indirect comparisons of acalabrutinib vs ibrutinib in treatment-naïve CLL

(3:20)

Matching-adjusted indirect comparison of Isa-Kd versus Dara-Rd in relapsed multiple myeloma

(1:44)

Overview of different indirect comparison approaches and methods

(40:2)

Trabectedin and pazopanib: an indirect comparison of their ability to treat LMS

(1:36)

Capacity: Indirect Comparison

(1:49)

Indirect Comparison in Length Measurement

(15:30)

Epcoritamab versus mosunetuzumab in patients with R/R FL: findings of a MAIC

(2:16)

Indirect Treatment Comparison Shows Momelotinib Has ‘Favorable’ Safety in Myelofibrosis

(5:25)

Everything you need to know about matching adjusted indirect comparisons

(42:5)

R for HTA 2022 Workshop - Erin Barker

(22:45)

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma

(3:56)

A 10 minutes introduction to Network Meta analysis Georgia Salanti

(10:30)